Albumin Recombinant Proteins 

Albumin recombinant proteins are synthetic versions of the naturally occurring albumin, typically derived from human serum albumin (HSA) or bovine serum albumin (BSA). These proteins are produced using advanced recombinant DNA technology in host systems such as E. coli, yeast (Pichia pastoris), or mammalian cell lines. The recombinant nature ensures high purity, reduced immunogenicity, and consistent batch-to-batch quality, making them superior to plasma-derived albumin for various applications.

Content:

Recombinant albumin is engineered to retain the structural integrity and functional properties of native albumin, including:

• Molecular Weight: Approximately 66 kDa, matching native albumin.
• Biochemical Properties: High solubility and stability, low endotoxin levels, and exceptional binding capacity for fatty acids, hormones, and drugs.
• GMP-Grade Purity: Suitable for use in clinical and pharmaceutical formulations, free from animal-derived contaminants.

Recombinant albumins are available in multiple isoforms and conjugates (e.g., albumin-fusion proteins or albumin-coated particles) to extend their utility in various specialized applications.

Applications:

• Cell Culture and Regenerative Medicine:
  • Serves as a critical supplement in serum-free and chemically defined media for culturing stem cells and other cell types.
  • Enhances cell growth, viability, and productivity in bioprocessing.
• Diagnostics and Assays:
  • Used as a blocking agent in ELISA, Western blotting, and immunohistochemistry to minimize non-specific binding.
  • Provides a stable protein scaffold for immobilization of antigens or antibodies in diagnostic platforms.
• Vaccine Development:
  • Stabilizes vaccine components during production and storage.
  • Minimizes degradation of recombinant antigens or adjuvants.
• Therapeutic Applications:
  • Explored in drug delivery systems, particularly for extending the half-life of therapeutic agents by leveraging albumin’s long circulatory persistence and receptor-mediated transcytosis.

Recombinant albumin proteins have revolutionized biomedical research and pharmaceutical production by offering a consistent, high-quality alternative to plasma-derived albumin, ensuring enhanced safety and performance in critical applications.